Premium
Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats
Author(s) -
Liberini Claudia G.,
Lhamo Rinzin,
Ghidewon Misgana,
Ling Tyler,
Juntereal Nina,
Chen Jack,
Cao Anh,
Stein Lauren M.,
Hayes Matthew R.
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13591
Subject(s) - liraglutide , medicine , endocrinology , weight gain , obesity , pregnancy , offspring , juvenile , lactation , body weight , diabetes mellitus , type 2 diabetes , biology , genetics
Aims To examine whether the glucagon‐like peptide‐1 receptor agonist liraglutide could be used in juvenile male and female rats as an anti‐obesity/diabetic pharmaceutical to prevent not only adolescent obesity/hyperglycaemia, but also early‐adult onset obesity. Material and Methods Pregnant dams were fed either standard chow or a high‐fat, high‐sucrose diet (HFSD) from gestational day 2, throughout pregnancy and lactation. Offspring were weaned onto the respective maternal diet. Juveniles received daily subcutaneous injection of liraglutide (50 μg/kg, from postnatal day [PND]30 to PND40 and 200 μg/kg from PND40 to PND60) or vehicle. Food intake, body weight and glycaemic levels were evaluated across the experimental period. Results Chronic liraglutide administration in juveniles prevented body weight gain in males and retained a normoglycaemic profile in both male and female rats. Conclusion These preclinical data suggest that maternal and early‐life consumption of an HFSD increases caloric intake, body weight gain and hyperglycaemia, a collective set of unwanted metabolic effects that appear to be treatable in juveniles with liraglutide pharmacotherapy intervention.